Pay in 4 interest-free payments of $5.68 Learn more
Ships within 48 hours · Estimated delivery Aug 30 - Sep 4
10.1093/ajhp/62.2.173 111
Summary: Retatrutide is an investigational triple hormone receptor agonist peptide (GLP-1, GIP, and glucagon) developed by Eli Lilly for obesity treatment, currently in Phase 3 trials and not yet approved by the MHRA or EMA
Cloning and functional expression of the human islet GLP-1 receptor
Anaheim Medical Groups commitment to patient-centered care ensures that individuals seeking IV Therapy in Anaheim receive top-notch treatment in a comfortable environment
US$ 28.56
US$ 23.53
US$ 22.98
US$ 29.00
US$ 22.89
US$ 23.61
US$ 27.19
